Answers are grounded in this paper and cite their sources.
Sir—Adding to an impressive body of work from the University of Alabama, Fowler et al. [1] contributed a number of new findings for understanding the risk of congenital cytomegalovirus (CMV) infection. On the basis of these results, they concluded that “the risk of congenital CMV increases, even when primary maternal infection occurs months and perhaps years before conception” and that “approximately one-half of the maternal primary infections that led to congenital CMV infection occurred >1 year before conception” [1, p. 1036]. Although it is biologically plausible that preconceptional CMV infection could pose a risk to the fetus, this risk appears to be overstated. In the study by Fowler and colleagues, much of the apparent increased risk was an artifact of women being pregnant for varying proportions of the interbirth intervals in which maternal seroconversion occurred. Consider a hypothetical example (figure 1) that uses the same study design and numbers of patients reported by Fowler et al. [1]. The example assumes that the mean interval between births is 18 months for the <24-month interbirth category, 36 months for the 25–48-month category, and 60 months for the >48-month category. Calculations of expected numbers assume that the probability of infection is equal at all times during each interval; that the probability of congenital infection is 35%, if maternal primary infection occurs during pregnancy; and that congenital infection results only from infection during pregnancy (i.e., there is no preconceptional risk). Because all women underwent seroconversion during the interval between births and there was equal probability of infection during the interval, the percentage of mothers infected during pregnancy was simply the proportion of the interval during which the women were pregnant. Risk of congenital cytomegalovirus (CMV) infection associated with maternal CMV seroconversion during the interval between births. The standardized risk ratio (SRR) was calculated by dividing the number of observed maternal seroconversions by the number of expected seroconversions. Observed data are from table 1 in the study by Fowler et al. [1]. Given these assumptions, how many congenital CMV infections would we expect to see in the study by Fowler and colleagues? In the hypothetical example (figure 1), the expected number of infected infants would be ∼15 (calculated value, 14.6), with a higher risk for women who had a shorter interval between 2 births, because these women were pregnant during a larger proportion of their respective interbirth intervals. Fowler et al. [1] observed 18 congenital infections, ∼3 (calculated value, 3.4; 23%) more than would be expected if preconceptional infection posed no risk. Thus, we would conclude that 19% of the congenital CMV infections (∼3 of 18) were attributable to preconceptional maternal infection and that 81% (∼15 of 18) were attributable to maternal infection during pregnancy. Modifying the assumptions about the mean interval between births and the probability of congenital infection would change the expected number of infected infants, but under most reasonable assumptions, the majority of congenital infections would still be attributable to maternal infection during pregnancy. Two important points emerge from this example. First, the 95% CIs for the standardized risk ratios (SRRs) all included the null value (SRR, 1), demonstrating that any link between preconceptional maternal CMV infections and congenital infections remains uncertain. In view of the large number of mothers observed by Fowler et al. [1], it will be difficult to perform a study that can definitively conclude that preconceptional maternal CMV infection causes congenital infection. Second, of the congenital infections that appeared to be attributable to preconceptional maternal infection, nearly all occurred in women whose mean interbirth interval was 18 months. Thus, these maternal infections occurred, on average, <9 months before conception. It makes biological sense that the risk increases immediately before conception, but the timing seriously contradicts the authors' assertion that “approximately one-half of the maternal primary infections that led to congenital CMV infection occurred >1 year before conception” [1, p. 1036]. In summary, data from the study by Fowler and colleagues suggest a modest but nonsignificant association between preconceptional maternal primary CMV infection and congenital infection. However, there is no evidence that maternal infection occurring >1 year before conception poses a risk to the fetus. Recently infected women can choose to delay pregnancy as a precaution, but women should know that CMV seropositivity before conception is protective and that pregnancy is the most important time to take measures to avoid exposure to CMV [2]. Potential conflicts of interest. All authors: no conflicts.
No takes yet. Share an insight, caveat, or question.
Cannon et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: